Cellular Prion Protein Enhances Drug Resistance of Colorectal Cancer Cells via Regulation of a Survival Signal Pathway.
10.4062/biomolther.2017.033
- Author:
Jun Hee LEE
1
;
Chul Won YUN
;
Sang Hun LEE
Author Information
1. Department of Pharmacology and Toxicology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA.
- Publication Type:Original Article
- Keywords:
Colorectal cancer;
Prion protein;
Drug resistance;
5-fluorouracil;
Anticancer
- MeSH:
Apoptosis;
Caspase 3;
Cell Survival;
Colorectal Neoplasms*;
Cyclin D1;
Cyclin E;
Cyclins;
Drug Resistance*;
Drug Therapy;
Fluorouracil;
Signal Transduction*
- From:Biomolecules & Therapeutics
2018;26(3):313-321
- CountryRepublic of Korea
- Language:English
-
Abstract:
Anti-cancer drug resistance is a major problem in colorectal cancer (CRC) research. Although several studies have revealed the mechanism of cancer drug resistance, molecular targets for chemotherapeutic combinations remain elusive. To address this issue, we focused on the expression of cellular prion protein (PrPC) in 5-FU-resistant CRC cells. In 5-FU-resistant CRC cells, PrPC expression is significantly increased, compared with that in normal CRC cells. In the presence of 5-FU, PrPC increased CRC cell survival and proliferation by maintaining the activation of the PI3K-Akt signaling pathway and the expression of cell cycle-associated proteins, including cyclin E, CDK2, cyclin D1, and CDK4. In addition, PrPC inhibited the activation of the stress-associated proteins p38, JNK, and p53. Moreover, after treatment of 5-FU-resistant CRC cells with 5-FU, silencing of PrPC triggered apoptosis via the activation of caspase-3. These results indicate that PrPC plays a key role in CRC drug resistance. The novel strategy of combining chemotherapy with PrPC targeting may yield efficacious treatments of colorectal cancer.
